Hyaluronidase Co-Administration Enhances Cancer Immunotherapy Efficacy Through Subcutaneous Delivery
Key Insights
Monash University researchers demonstrate that subcutaneous administration of cancer (search) immunotherapies with hyaluronidase is more effective than traditional intravenous delivery for the first time.
The enzyme hyaluronidase breaks down hyaluronan in subcutaneous tissue, enabling high-volume injections while improving treatment access to the lymphatic system (search) where immune responses are generated.
This delivery method offers dual benefits of enhanced therapeutic efficacy and improved patient convenience by reducing treatment complexity and pain compared to intravenous infusion.
Researchers at Monash University, in collaboration with Halozyme Therapeutics, have demonstrated for the first time that subcutaneous administration of cancer (search) immunotherapies with hyaluronidase not only improves patient convenience but also enhances treatment efficacy. The study, published in Cancer Immunology Research, challenges the conventional approach to delivering monoclonal antibody (search) immunotherapies and offers a promising new strategy for cancer treatment.
Breaking Down Delivery Barriers
Monoclonal antibody (search) immunotherapies typically require high doses and volumes to be effective, necessitating intravenous infusion. While subcutaneous administration is increasingly preferred by patients due to its convenience and reduced pain, this method has been limited by the inability to inject large volumes under the skin.
Halozyme Therapeutics developed a recombinant version of hyaluronidase, an enzyme that addresses this limitation. When co-administered in subcutaneous injections, hyaluronidase transiently breaks down hyaluronan, a structural component in subcutaneous tissue that restricts large-volume injections. This breakdown occurs almost immediately, making the transition from intravenous to subcutaneous delivery possible.
Enhanced Therapeutic Efficacy
"We show here, for the first time, that for some treatments that help the immune system fight cancer (search), when they are co-administered subcutaneously with hyaluronidase, they are indeed more effective and hyaluronidase is able to 'boost' the benefit of subcutaneous administration," said Professor Chris Porter, co-lead author from the Monash Institute of Pharmaceutical Sciences.
The enhanced efficacy stems from improved access to the lymphatic system (search), where immune responses are generated. Co-lead author Dr. Gracia Gracia explained that this subcutaneous approach with hyaluronidase helps treatments reach the lymphatic system more effectively than traditional intravenous delivery.
Targeting the Lymphatic System
The lymphatic system (search) plays a crucial role in certain cancers, particularly those involving tumor-draining lymph nodes (search). "Because the lymphatic system plays an important role in certain cancers—particularly those involving tumor-draining lymph nodes—delivering treatment directly to this system may be a promising therapeutic approach," Dr. Gracia noted.
This targeted delivery mechanism is particularly relevant for anticancer immunotherapies, many of which act at tumor-draining lymph nodes (search). The study provides additional rationale for adopting this approach for therapeutics that target these specific anatomical sites.
Industry Collaboration and Future Implications
Dr. David Kang, Director of Drug Delivery and Innovation at Halozyme Therapeutics, described the research as "the culmination of a long collaboration with MIPS to examine how co-administration with hyaluronidase might improve access to the lymphatic system (search) after subcutaneous administration compared with intravenous administration."
The findings suggest that transitioning from intravenous to subcutaneous administration offers dual benefits: improved convenience and reduced patient discomfort, while potentially enhancing therapeutic outcomes. This represents a significant advancement in cancer (search) immunotherapy delivery, addressing both patient quality of life and treatment efficacy concerns.
The research opens new avenues for optimizing cancer (search) immunotherapy delivery and may influence how future monoclonal antibody (search) treatments are administered, particularly those targeting the lymphatic system (search) and tumor-draining lymph nodes (search).